RIO DE JANEIRO, May 7. /TASS/. Uniao Quimica will start producing the Sputnik V coronavirus vaccine in Brazil before the national regulator (Anvisa) gives its approval, CEO of the Brazilian pharmaceutical company Fernando Marques said on Friday. We will get a batch of the active component from Moscow next week and will start bottling the vaccine at the plant in Guarulhos, he said. We will start production immediately after receiving components and will await registration enabling us to start its use in the country, Marques noted.
Production of the active component in Brazil is to start after receiving a conclusion from the Gamaleya Research Center, the vaccine developer, the top manager said. We will receive equipment in late May, making it possible to scale up production volumes, he added.
Brazilian official lashes at watchdog for its decision on Sputnik V
According to Vilas-Boas, the watchdogâs refusal to authorize imports of the Russian vaccine is unjustified
RIO DE JANIERO, April 28. /TASS/. The Brazilian Health Regulatory Agency (Anvisa), which refused to authorize imports of Russia’s Sputnik V anti-coronavirus vaccine, has completely ignored the real epidemiological situation in the country, the chief healthcare official of Brazil’s state of Bahia, Fabio Vilas-Boas, said on Tuesday. In our joint opinion with [local pharmaceutical company] BahiaPharma, Anvisa will require no less than six months to have all questions answered. The demands that it had voiced are absolutely detached from reality, he said in an interview with Globo TV.
Brazilâs regulator not allowing Sputnik Vâs import due to political reasons - developers
The delay by Anvisa to issue permission for the import and use of the Sputnik V vaccine has nothing to do with access to data on the vaccine or science, the vaccineâs Twitter account said
MOSCOW, April 27. /TASS/. Developers of Russia’s Sputnik V COVID-19 vaccine believe that the refusal of the Brazilian Health Regulatory Agency (Anvisa) to allow its import is politically motivated, the vaccine’s Twitter account said. The delay by the Brazilian Health Regulatory Agency (Anvisa) to issue permission for the import and use of the Sputnik V vaccine in the country is unfortunately of political nature and has nothing to do with access to data on the vaccine or science, the developers said on their official Twitter account.
Brazilian watchdog requests court to extend Sputnik V review period
Earlier, the court authorized importing Sputnik V to Brazil without the national pharmaceutical regulator s approval, if the governmental agency fails to make any decision regarding its use by the end of April
RIO DE JANEIRO, April 21. /TASS/. Brazil’s National Health Surveillance Agency (Anvisa) requested the country’s Federal Supreme Court to give it more time for considering a registration request for Russia’s Sputnik V anti-coronavirus vaccine, the Globo TV channel has reported.
According to the channel, the watchdog says it is impossible to authorize the use of the vaccine, because there has been insufficient information about the vaccine’s quality, effectiveness and safety. At the same time, Anvisa earlier confirmed receiving documents on Sputnik V from Argentina, which successfully uses the Russian vaccine.